Other substances

Azanitrile 8

A protease inhibitro.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
21
 Clinical trials

General information

Azanitrile 8 is a SARS-CoV-2 3C-like protease experimental irreversible inhibitor (Breidenbach et al., 2021).

(Structure image generated in SwissSimilarity)

Synonyms

Gü3619; 8

 

Structure image - Azanitrile 8

CC[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N(C)N(CCC(N)=O)C#N)C(C)(C)C

Supporting references

Link Tested on Impact factor Notes Publication date
Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
3CLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay 12.96

Inhibited SARS-CoV-2 3C-like protease with an IC50 of ca. 0.0378 μM in vitro.

 Mar/03/2021

AI-suggested references

Link Publication date
Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
Mar/24/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04756817 Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece Recruiting Feb/13/2021 Sep/30/2021
  • Alternative id - 2/27.1.2021
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - G. Gennimatas General Hospital, Thessaloníki, Thessaloniki, Greece
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 500
  • Age - 85 Years to 100 Years   (Older Adult)
  • Outcome measures - Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine|Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19 vaccine|Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19|PCR-confirmed cases of SARS-CoV-2 infection anytime after the first dose.
NCT05060978 Evaluation of the Effect of Two Online Interventions -Watch Your Weight During the Holidays Program and the Relative 5:2 Fasting- for the Prevention of Body Weight Gain at 8 Weeks in Mexican Adults in the Covid-19 Pandemic Active, not recruiting Not Applicable Nov/10/2021 Nov/01/2022
  • Alternative id - USO313007128
  • Interventions - Behavioral: Watch your Weight During the Holidays Program|Other: Relative 5:2 Fasting|Other: Control Group
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Centro de Promoción de Salud Nutricional (CPSN), Hermosillo, Sonora, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 32
  • Age - 20 Years to 60 Years   (Adult)
  • Outcome measures - Changes in body weight|Changes in kilograms of body fat|Changes in waist circumference|Changes in systolic blood pressure|Changes in diastolic blood pressure|Changes in perception of health related quality of life|Retention / desertion|Adherence to intervention|Participant satisfaction scale|Changes in fasting glucose|Changes in total cholesterol|Changes in LDL cholesterol|Changes in HDL cholesterol|Changes in triglycerides
NCT05035524 A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 Active, not recruiting Not Applicable Sep/01/2021 Mar/01/2022
  • Alternative id - SB-COVID
  • Interventions - Drug: Sodium Bicarbonate Solution|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mansoura University Hospital - Chest Departement, Mansoura, DK, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 340
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The time interval to recovery defined as the first day
NCT04456088 Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial) Withdrawn Phase 2 Jul/15/2020 Dec/15/2020
  • Alternative id - BAI_COV19_01_CAN
  • Interventions - Combination Product: 150 ppm Nitric Oxide delivered through LungFit Delivery System|Combination Product: 80 ppm Nitric Oxide delivered through LungFit Delivery System
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 22 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Time to deterioration|Time to stable oxygen saturation
NCT04363840 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Withdrawn Phase 2 May/01/2020 Dec/01/2020
  • Alternative id - 20-063
  • Interventions - Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalization
NCT04664023 Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution Recruiting Dec/09/2020 Dec/30/2022
  • Alternative id - BIOMARK-COVID
  • Interventions - Procedure: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|Procedure: Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers
  • Study type - Observational
  • Study results - No Results Available
  • Locations - C.H.U.de Poitiers, Poitiers, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 180
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Neutralizing antibodies|T CD8 lymphocytes|Inflammatory markers|Metabolic markers
NCT04755972 Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2 Completed Not Applicable Oct/01/2020 Jul/29/2021
  • Alternative id - 2181-147-01/06/M.S.-20-02
  • Interventions - Other: Inhalation of N-acetylcysteine|Other: Inhalation of 5% sodium chloride|Other: Inhalation of 8,4% sodium bicarbonate
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinical Hospital Centre Split, Split, Croatia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 175
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Difference between 4 arms regarding ventilator-associated pneumonia rate|Number of ventilator-free days|Mortality
NCT04340349 Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals Enrolling by invitation Early Phase 1 Feb/01/2021 Jun/30/2021
  • Alternative id - 25/20
  • Interventions - Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - National Institute of Rehabilitation, Luis Guillermo Ibarra Ibarra, Mexico City, Cdmx, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 214
  • Age - 18 Years to 59 Years   (Adult)
  • Outcome measures - Quantification of the expression of mRNA SARS-CoV-2 and presence or absence of antibodies anti-SARS-CoV-2
NCT04935476 Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 Recruiting Phase 3 Nov/22/2021 Jul/31/2022
  • Alternative id - PDC01
  • Interventions - Drug: Dapsone 85 mg PO BID|Drug: Placebo 85 mg PO BID
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Arizona Pulmonary and Medical Specialists, Phoenix, Arizona, United States|Peters Medical Research, LLC, High Point, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States|Principle Research Solutions, Spokane, Washington, United States|Inspiration Research Limited, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 3000
  • Age - 40 Years and older   (Adult, Older Adult)
  • Outcome measures - Composite outcome: All cause pre-hospitalization death or all-cause hospitalization|Severe complications (composite outcome: All cause ICU admission, invasive ventilation or pre- or post-hospitalization death)|All-cause ICU admission|Intubation with mechanical ventilation|All-cause death|Hospitalization with all-cause requirement of supplemental oxygen|Length of hospital stay among participants|Drug safety (Adverse Event (AE) and Serious Adverse Event (SAE)) for short term therapy in COVID-19 patients|Patient reported outcome (e.g. patient reported COVID-19 related symptoms)
NCT04355247 Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm Recruiting Phase 2 Apr/14/2020 Apr/30/2021
  • Alternative id - CCAM 20-01
  • Interventions - Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 20
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria
NCT04693689 Novelty, Conformity and Trust in COVID-19 Vaccines Completed Not Applicable Feb/01/2021 Mar/30/2021
  • Alternative id - SG-Trust in Vaccines
  • Interventions - Other: RNA vaccine|Other: 20% adoption rate|Other: 40% adoption rate|Other: 60% adoption rate|Other: 80% adoption rate|Other: Conventional vaccine|Other: 0% adoption rate
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SurveyMonkey, San Mateo, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research
  • Enrollment - 35180
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Willingness to receive COVID-19 vaccine|Belief in how much COVID-19 vaccine should be subsidized by the government|Belief in importance of vaccinating children|Belief in safety of vaccines|Belief in effectiveness of vaccines|Dishonesty index
NCT04355936 Telmisartan for Treatment of COVID-19 Patients Completed Phase 4 May/19/2020 Nov/30/2020
  • Alternative id - 2020-001
  • Interventions - Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital Español de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - C reactive protein|Admission to intensive care unit (ICU)|Occurrence of mechanical ventilation|Death|Composite occurrence of admission to ICU, mechanical ventilation or death (what occur first)|Time from randomization to discharge|Proportion of patients not requiring supplemental oxygen at day 15|Significative differences in serum lactate dehydrogenase
NCT04380519 Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) Completed Phase 2|Phase 3 Apr/23/2020 Jul/24/2020
  • Alternative id - CL04041078
  • Interventions - Drug: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Private healthcare institution "Clinical Hospital" Russian Railways-Medicine named after N. A. Semashko", Moscow, Russian Federation|State Budget Healthcare Institution "City Clinical Hospital № 15 named after O.M. Filatov" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution "Federal Center for Cerebrovascular Pathology and Stroke" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Autonomous Education Institution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of the Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budgetary Institution "Central Clinical Hospital with Polyclinic" of Administrative Directorate of the President of the Russian Federation, Moscow, Russian Federation|Federal State Budget Institution "National Medicine Research Center on Cardiology" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare "City Clinical Hospital #52", Moscow City Healthcare Department, Moscow, Russian Federation|State budgetary healthcare institution City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the city of Moscow City Clinical Hospital No. 50, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare "Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare", Moscow, Russian Federation|АО "State Company "Medsi" based on Clinical Hospital №1", Moscow, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "Volga Research Medical University" of the Ministry of Health of the Russian Federation, Nizhniy Novgorod, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare "City Hospital №40", Saint Petersburg, Russian Federation|Federal Budgetary State Healthcare Institution "National Medical Research Center named after B.A. Almazov", Saint-Petersburg, Russian Federation|Budgetary Health Institution Voronezh Regional Clinical Hospital №1, Voronezh, Russian Federation|State Budget Healthcare Institution of Yaroslavl Region "Yaroslavl Region Clinical Hospital of War Veterans", Yaroslavl, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 372
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of Responders in Each Treatment Group|Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale|The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab|The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study|Mortality Rate During the Study
NCT04341441 Will Hydroxychloroquine Impede or Prevent COVID-19 Terminated Phase 3 Apr/07/2020 Dec/15/2020
  • Alternative id - 1410401
  • Interventions - Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 624
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.
NCT05156671 Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial Not yet recruiting Phase 2 Mar/01/2022 Jun/01/2023
  • Alternative id - AGNES-19
  • Interventions - Biological: Adrecizumab (HAM 8101)|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 218
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to clinical improvement|Clinical status at day 28, as measured on the WHO 8-point ordinal scale|Survival (time-to-event) until day 28 and end of follow-up (90 days)|Rate of invasive mechanical ventilation until day 28 and day 90|Length of invasive mechanical ventilation until day 28 and day 90|Rate of ECMO therapy until day 28 and day 90|Length of ECMO therapy until day 28 and day 90|Length of stay at ICU after application of IMP up to a total of 90 days|Length of hospital stay after application of IMP up to a total of 90 days|All-cause rehospitalisation within 90 days|Rate of renal replacement therapy until day 28 and day 90|Change in clinical status on the WHO 8-point ordinal scale for COVID-19 at days 7, 28, and 90|Change in SOFA score sum (only during hospitalization on ICU) with-in 24 hours of IMP administration (start of infusion), 48 hours, day 7 post-infusion|Between-group difference in life quality as assessed by EQ-5D-5L at discharge, day 28, day 90
NCT05046652 Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series Completed Apr/01/2020 Dec/31/2020
  • Alternative id - 0408087106
  • Interventions - Biological: Convalescent Plasma Therapy
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Theresia Monica Monica, Bandung, West Java, Indonesia
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 8
  • Age - Child, Adult, Older Adult
  • Outcome measures - Patients with two doses of CP tended to have faster recovery than those with one dose of CP.|Patients with two doses of CP tended to have faster PCR negative conversion time than those with one dose of CP
NCT04470297 Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19 Not yet recruiting Phase 2 Sep/01/2020 Mar/01/2021
  • Alternative id - MELCOV2020
  • Interventions - Drug: Ramelteon 8mg
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0]|Clinical worsening to critical COVID-19 illness|Duration of supplemental oxygen therapy|Duration of mechanical ventilation (if applicable)|Duration of hospitalisation|Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR|C-reactive protein (CRP) level's reduction|Incidence of New Onset Lymphopenia|Direct bilirubin level's reduction|Side Effects
NCT05157178 Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses. Active, not recruiting Phase 4 Jun/20/2021 Jun/27/2022
  • Alternative id - ASCLIN 004/2021
  • Interventions - Biological: Covid-19 (recombinante) vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Policlinica Lincoln de Freitas Filho, Rio de Janeiro, Brazil|Unidade de Ensaios Clínicos em Imunobiológicos, Rio de Janeiro, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 1264
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Geometric mean titers of IgG Anti-S antibody after two doses of Covid-19 (recombinante)|Seroconversion of IgG Anti-S antibodies after two doses of Covid-19 (recombinante) vaccination|Seroconversion of IgG Anti-S antibodies after two doses of Covid-19 (recombinante) by serologic status before vaccination|Geometric mean titer of Anti-S IgG antibodies 6 and 12 months after Covid-19 (recombinante) vaccination|Reactogenicity and Safety of Covid-19 (recombinante) vaccine
NCT04844658 Covid-19, Hospitalized, PatIents, Nasafytol Completed Not Applicable Feb/17/2021 Oct/29/2021
  • Alternative id - CHOPIN
  • Interventions - Drug: NASAFYTOL®|Drug: FULTIUM® -D3 800
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Delta Hospital, Brussels, Belgium
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 51
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Improvement of the patient's clinical condition based on the WHO ordinal outcomes score|Duration of hospitalization|In-hospital mortality|Temperature (fever)|Need of oxygen therapy|Tolerance as defined by the Incidence of Adverse Events (AE)|Tolerance as defined by the incident of Serious Adverse Events (SAE)|Compliance using the pill count|Blood test
NCT04405570 Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 Completed Phase 2 Jun/19/2020 Feb/21/2021
  • Alternative id - EIDD-2801-2003
  • Interventions - Drug: Molnupiravir 200 mg|Drug: Molnupiravir 400 mg|Drug: Molnupiravir 800 mg|Drug: Placebo (PBO)
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Valley Clinical Trials, Inc., Northridge, California, United States|FOMAT Medical Research, Oxnard, California, United States|Southern California Emergency Medicine, Yucaipa, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|NOLA Research Works, LLC, New Orleans, Louisiana, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Care United Research, LLC, Forney, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 204
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs|Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs|Number of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment|Number of Participants With Any Adverse Events (AEs), Grade 2 or Higher
NCT04900155 Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 Recruiting Not Applicable Nov/20/2020 May/01/2022
  • Alternative id - PSU/T-487
  • Interventions - Drug: Atorvastatin 80mg|Drug: Atorvastatin-Ezetimibe
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Valentin Oleynikov, Penza, Russian Federation
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 30 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Lipid profile assessment|Assessment of ventricular rhythm disturbances|Electrical instability and autonomic regulation of heart rate|Left ventricular systolic function|Left ventricular myocardial deformation (strain, strain rate)|Number of Participants with major cardiovascular events
Export (.csv)